Critical Outcome Technologies Inc. Completes Financing

Critical Outcome Technologies Inc. (TSX VENTURE:COT) ("COTI" or the
"Corporation") the bioinformatics and accelerated drug discovery company, is
pleased to announce the completion of the final tranche of its previously
announced non-brokered private placement with the issuance of 5,595,135 units
(the "Units") at a price of $0.16 per Unit for gross proceeds of approximately
$895,000. In aggregate, the Corporation raised gross proceeds from the offering
of approximately $1,432,000 through the sale of 8,951,385 Units. 


"This financing supports our ongoing operations in advancing our lead cancer
drug candidate, COTI-2, into a Phase 1 clinical trial by the end of this year,"
said John Drake, Chairman of the Board. "Our near term milestones are
progressing nicely. We recently completed the dosing and post-dosing observation
segments of the final pre-clinical two-species toxicity studies and are excited
to have the resources and investor support to complete the necessary work for
filing the Investigational New Drug application for COTI-2 late this summer.
These are important risk reduction and value creating events that will enhance
the attractiveness of COTI-2 for licensing." 


"We are proud of the progress we have made and look forward to getting into the
clinic," said Dr. Wayne Danter, President and Chief Executive Officer. "We will
then be able to expand upon the preclinical work demonstrating that COTI-2 is
potentially transformational in the treatment of ovarian cancer and other
cancers where there is a p53 gene mutation present in afflicted patients." 


Each Unit consists of one common share and one warrant of the Corporation. Each
warrant is exercisable for one common share of the Corporation at an exercise
price of $0.28 per share for a period of 24 months from the date of issue. The
Corporation paid finders' fees to arm's length third parties in connection with
this tranche in the amount of $35,058 in cash and issued 219,110 compensation
warrants. In aggregate, the Corporation paid finders' fees of $73,777 in cash
and issued 461,110 compensation warrants in connection with the offering. Each
compensation warrant is exercisable into one common share of the Corporation at
an exercise price of $0.22 per share for a period of 24 months from the date of
issue. 


The common shares and warrants issued by the Corporation under the offering are
subject to restrictions on resale in accordance with applicable securities laws
and the policies of the TSX Venture Exchange. These restrictions will expire on
September 1, 2014 for the securities issued on the first closing and October 4,
2014 for this final closing. The offering is subject to final acceptance by the
TSX Venture Exchange. 


About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge bioinformatics company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI's proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Notice to Readers 

Information contained in this press release may contain certain statements,
which constitute "forward-looking statements" within the meaning of the
Securities Act (Ontario) and applicable securities laws. For example, the
statement, "... in advancing our lead cancer drug candidate, COTI-2, into a
Phase 1 clinical trial by the end of this year" and "... to complete the
necessary work for filing the Investigational New Drug application for COTI-2
late this summer. These are important risk reduction and value creating events
that will enhance the attractiveness of COTI-2 for licensing" are
forward-looking statements. Forward-looking statements by their nature are not
guarantees of future performance and are based upon management's current
expectations, estimates, projections and assumptions. COTI operates in a highly
competitive environment that involves significant risks and uncertainties, which
could cause actual results to differ materially from those anticipated in these
forward-looking statements. Management of COTI considers the assumptions on
which these forward-looking statements are based to be reasonable, but as a
result of the many risk factors, cautions the reader that actual results could
differ materially from those expressed or implied in these forward-looking
statements. Information in this press release should be considered accurate only
as of the date of the release and may be superseded by more recent information
disclosed in later press releases, filings with the securities regulatory
authorities or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
[e-mail]
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
[e-mail]